Real World Data Helping To Drive Rise Of Novartis' Entresto

Patients with heart failure on Entresto say they have fewer symptoms and greater quality of life, according to a registry study and Novartis is hoping that this and other real world data will propel the drug towards its peak sales target of $5bn.

Hand holding digital tablet with global network connection technology and modern buildings. Element of this image are furnished by NASA
Entresto real-world data adds to strong clinical package • Source: Shutterstock

After getting off to an extremely slow start, sales of Novartis AG's heart failure drug Entresto (sacubitril/valsartan) are rocketing and the Swiss major has presented more real-world data that it hopes will convince physicians and payers even more about the benefits of the therapy.

Interim findings from the CHAMP-HF registry have been unveiled at the European Society of Cardiology Heart Failure congress in Vienna,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

More from Therapeutic Category